Luther T. Clark, MD, FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, December 1, 2011. Dr. Clark's presentation will take place at 12:00 noon in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, New York 11203.
Dr. Clark's remarks will cover how "Hit" molecules are identified and modified to become "Lead" compounds in the high-risk drug (nonpeptide) discovery process; the distinction between pharmacodynamics and pharmacokinetics of compounds; and the necessary efficacy and safety assessments that must occur before a molecule is considered a preclinical candidate.
Dr. Clark is the global director for scientific affairs (GDSA) for atherosclerosis, in the Office of the Chief Medical Officer at Merck. Before joining Merck in April 2007, he was chief of the Division of Cardiovascular Medicine and professor of clinical medicine at the SUNY Downstate Medical Center and Kings County Hospital Center, Brooklyn, New York. He was also director and principal investigator of the NIH-supported Brooklyn Health Disparities Research Center. He has authored more than 100 publications and edited the textbook, Cardiovascular Disease and Diabetes (McGraw-Hill 2007).
Dr. Clark is a fellow of the American College of Cardiology and the American College of Physicians, a past member of the Board of Directors of the Heritage Affiliate of the American Heart Association, and a past member of the New York State Cardiac Advisory Committee. He has served on a number of National Heart, Lung, and Blood Institute committees, including the CARDIA (Coronary Artery Risk Development in Young Adults) Review Board, the National Cholesterol Education Program (NCEP), and the NCEP's Expert Panels on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP I, ATP II, ATP III, and 2004 Update). Dr. Clark earned his bachelor of arts degree from Harvard College, Cambr
|Contact: Ron Najman|
SUNY Downstate Medical Center